The research company Hamlet Biopharma is provided with approximately SEK 8.5 million before issue costs through the exercise of short options of series TO5B. In total, just over 1.4 million new B shares were subscribed at a price of SEK 6 per share.The company states that the capital is being raised at a time of continued development work and dialogue about a partnership in bladder cancer. The next subscription period runs 20–31 July 2026."We are raising capital at a stage where we have momentum in the business and a clear direction forward. As previously announced, we have a non-binding Letter of Intent with a pharmaceutical company specialized in uro-oncology based in northern Germany. The aim is to establish terms and frameworks for the completion of drug development and the global commercialization of Alpha 1H for the treatment of bladder cancer. The dialogue remains highly constructive and forward-looking, with a focus on completing the clinical development, scaling up manufacturing, and establishing commercial frameworks to reach the market. The collaboration would give us the opportunity to create long-term value for patients, healthcare systems, and shareholders, subject to successful study results and marketing authorization," says Catharina Svanborg, chair of Hamlet Biopharma, in a comment.